Wholesales Ibrutinib CAS 1177-87-3 with Low Price
China Wholesales Ibrutinib CAS 1177-87-3 with Low Price, Find details about China Angiogenesis, Small Molecule Inhibitors from Wholesales Ibrutinib CAS 1177-87-3 with Low Price
Basic Info.
Model NO.
Ibrutinib
Product Name
Ibrutinib
Brand Name
Biocar
CAS No.
936563-96-1
Molecular Formula
C25h24n6o2
Molecular Weight
440.5
Apearance
White Powder
Deliver Time
7-10 Days
Einecs No.
805-642-2
Shelf Life
2 Years
Trademark
Biocar
Transport Package
Bag or Drum
Specification
1kg/bag; 25kg/drum
Origin
China
HS Code
29372290
Model NO.
Ibrutinib
Product Name
Ibrutinib
Brand Name
Biocar
CAS No.
936563-96-1
Molecular Formula
C25h24n6o2
Molecular Weight
440.5
Apearance
White Powder
Deliver Time
7-10 Days
Einecs No.
805-642-2
Shelf Life
2 Years
Trademark
Biocar
Transport Package
Bag or Drum
Specification
1kg/bag; 25kg/drum
Origin
China
HS Code
29372290
Product Desciption
Wholesales Ibrutinib CAS 1177-87-3 with Low Price
Detailed Product Information
| Product Name | Ibrutinib |
| CAS No. | 936563-96-1 |
| Apearance | White Powder |
| Molecular Formula | C25H24N6O2 |
| EINECS No. | 805-642-2 |
| Molecular Weight | 440.5 |
| Brand Name | Biocar |
| Shelf Life | 2 Years |
| Delivery Time | 7-10 Days |
Description:
Ibrutinib is a Bruton tyrosine kinase (Btk) inhibitor for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Both MCL and CLL belong to B-cell non-Hodgkin lymphoma, which is difficult to cure and easy to relapse. The commonly used chemoimmunotherapy does not have targeting, and grade 3 or 4 adverse reactions often occur. Irutinib can combine with Btk, which is necessary for the formation, differentiation, information transmission and survival of B lymphocytes, irreversibly inhibit the activity of BTK and effectively inhibit the proliferation and survival of tumor cells; It can be absorbed rapidly after oral administration, reaching the maximum plasma concentration in 1 ~ 2H. The adverse reactions belong to grade 1 or 2. It will become a new choice for the treatment of CLL and MCL. On November 13, 2013, the U.S. Food and Drug Administration (FDA) accelerated the approval of pharma chemical Book cycles and J & J's imbruvica (common name: ibrutinib, ibrutinib) for the treatment of mantle cell lymphoma (MCL), a rare invasive blood cancer. Ibrutinib is an oral Bruton tyrosine kinase (Btk) The first new drug of inhibitor was granted the qualification of breakthrough therapeutic drug by FDA in February 2013, and was approved as the therapeutic drug of MCL and CLL on November 13, 2013 and February 12, 2014 respectively. The drug passes through the cysteine residue (cys-481) at the active site of target protein Btk Selectively covalently bind and irreversibly inhibit Btk, so as to effectively prevent tumor migration from B cells to lymphoid tissue suitable for tumor growth environment.
Ibrutinib is a Bruton tyrosine kinase (Btk) inhibitor for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Both MCL and CLL belong to B-cell non-Hodgkin lymphoma, which is difficult to cure and easy to relapse. The commonly used chemoimmunotherapy does not have targeting, and grade 3 or 4 adverse reactions often occur. Irutinib can combine with Btk, which is necessary for the formation, differentiation, information transmission and survival of B lymphocytes, irreversibly inhibit the activity of BTK and effectively inhibit the proliferation and survival of tumor cells; It can be absorbed rapidly after oral administration, reaching the maximum plasma concentration in 1 ~ 2H. The adverse reactions belong to grade 1 or 2. It will become a new choice for the treatment of CLL and MCL. On November 13, 2013, the U.S. Food and Drug Administration (FDA) accelerated the approval of pharma chemical Book cycles and J & J's imbruvica (common name: ibrutinib, ibrutinib) for the treatment of mantle cell lymphoma (MCL), a rare invasive blood cancer. Ibrutinib is an oral Bruton tyrosine kinase (Btk) The first new drug of inhibitor was granted the qualification of breakthrough therapeutic drug by FDA in February 2013, and was approved as the therapeutic drug of MCL and CLL on November 13, 2013 and February 12, 2014 respectively. The drug passes through the cysteine residue (cys-481) at the active site of target protein Btk Selectively covalently bind and irreversibly inhibit Btk, so as to effectively prevent tumor migration from B cells to lymphoid tissue suitable for tumor growth environment.
Our services
1. We has almost 7 years' exporting experience in active pharmaceutical ingredint products.
Our professional and thoughtful after-sales service eliminates your worries.
2.We can provide you with ten thousands of products of different levels.
3. We offer convenient one-station purchasing service.
1>Any inquiries will be replied within 12 hours.
2> Dedication to quality, supply & service.
3> Strictly on selecting raw materials.
4> Reasonable & competitive price, fast lead time.
You Might Also Like
Triac 0-10V Dali Dimmable Recessed LED Downlight/ COB LED Ce......
GMP Factory Supply Food Grade Phycocyanin Spirulina Extract
Table Tennis Racket with Rubber + Bag Ping Pong Bat
3mh Cool Giant Fat Inflatable Cat Cartoon for Advertising
Mslfp14 17*17 Wired Box Size X-ray Digital Flat Panel Detect......
Portable Glass Shape Edge Polishing Machine
A4 A3 Paper Wrapping Machine
Stainless Steel Angle Tube Strainer
Sinchold 9220/20/45 Forged Steel Welded Crane Rail Clips
Warehouse Tent Made by Superb Tent
Thyristor Rectified CO2 MIG Mag Arc Welding Machine